Skip to main content
. Author manuscript; available in PMC: 2022 Jun 9.
Published in final edited form as: Adv Funct Mater. 2021 Apr 10;31(24):2100478. doi: 10.1002/adfm.202100478

Fig. 4. Long-term therapeutic efficacy of iRGD-liposome-ASO in CRPC tumors.

Fig. 4.

The 22Rv1 tumor-bearing mice were treated with PBS, free ASO, and iRGD-liposome-ASO, respectively. The ASO dose was 50 mg/kg and the injections were given every four days for two weeks. The long-term effect of iRGD-liposome-ASO are presented after 4 months of treatment by the growth curve of tumor volume (A), images of tumor (B), and the tumor weight by the end of observation (C). All experiments were performed in 5–6 mice per group. The data are represented as mean ± standard deviation (SD). *P<0.05, ** P<0.01, ***P<0.001, **** P<0.0001.